These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 17850733)

  • 21. Patient-Reported Outcomes in Latin America: Implementation in Research and Role in Emerging HTA Systems.
    Winnette R; Zárate V; Machnicki G; DeMuro C; Gawlicki M; Gnanasakthy A
    Value Health Reg Issues; 2015 Dec; 8():49-55. PubMed ID: 29698171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New drugs for perinatal practice: the role of industry-sponsored clinical trials.
    Long W; Zeng G; Henry GW
    Semin Perinatol; 1995 Apr; 19(2):132-43. PubMed ID: 7604304
    [No Abstract]   [Full Text] [Related]  

  • 24. Brand-name drug companies fail to meet R&D commitments.
    Kondro W
    CMAJ; 2006 Aug; 175(4):344. PubMed ID: 16908891
    [No Abstract]   [Full Text] [Related]  

  • 25. [Insights into neurological drug development in Japan].
    Nakamura H; Uyama Y
    Brain Nerve; 2012 Mar; 64(3):229-35. PubMed ID: 22402716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Latin American nephrology: scientific production and impact of the publications.
    Weisinger JR; Bellorín-Font E
    Kidney Int; 1999 Oct; 56(4):1584-90. PubMed ID: 10504512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Involving the pharmaceutical and biotech communities in medication development for substance abuse.
    Gorodetzky CW; Grudzinskas C
    Pharmacol Ther; 2005 Oct; 108(1):109-18. PubMed ID: 16038981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conducting clinical trials in Singapore.
    Woo KT
    Singapore Med J; 1999 Apr; 40(4):310-3. PubMed ID: 10487091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Attractiveness of France for clinical trials: evaluation of laboratories and promoters].
    d'Enfert J; Lassale C; Prod'homme P
    Therapie; 2003; 58(3):283-9. PubMed ID: 14655322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Facilitating large-scale clinical trials: in Asia.
    Choi HY; Ko JW
    Urol Oncol; 2010; 28(6):691-2. PubMed ID: 21062654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacoeconomic component of a clinical trial conducted in Latin America. Conceptual and empirical considerations.
    Reinharz D; Saldaña VR; Follador W; Asche C
    Int J Technol Assess Health Care; 2001; 17(4):571-8. PubMed ID: 11758300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Managing clinical grant costs.
    Glass HE; Hollander K
    Contemp Clin Trials; 2009 May; 30(3):221-6. PubMed ID: 19470309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surviving the blockbuster syndrome.
    Service RF
    Science; 2004 Mar; 303(5665):1796-9. PubMed ID: 15031490
    [No Abstract]   [Full Text] [Related]  

  • 34. Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development.
    Spellberg B; Miller LG; Kuo MN; Bradley J; Scheld WM; Edwards JE
    Infection; 2007 Jun; 35(3):167-74. PubMed ID: 17565458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. India remains on US trade "priority watch list" for failing to uphold international drug company patents.
    Arie S
    BMJ; 2013 May; 346():f2949. PubMed ID: 23657189
    [No Abstract]   [Full Text] [Related]  

  • 36. IP litigation in China could drive innovation.
    Jia H
    Nat Biotechnol; 2004 Apr; 22(4):368. PubMed ID: 15060539
    [No Abstract]   [Full Text] [Related]  

  • 37. Patent indicators: a window to pharmaceutical market success.
    Guo Y; Hu Y; Zheng M; Wang Y
    Expert Opin Ther Pat; 2013 Jul; 23(7):765-71. PubMed ID: 23611022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An update on anti-allergic patents granted in China: 2009 - 2011.
    Zhang S; Zeng X; He S
    Expert Opin Ther Pat; 2012 Jul; 22(7):715-34. PubMed ID: 22702413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategic options for brand-name prescription drugs when patents expire.
    Mehta SC; Mehta SS
    Health Mark Q; 1997; 14(3):107-14. PubMed ID: 10167309
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The cost of Latin American science Introduction for the second issue of CBP-Latin America.
    Zenteno-Savín T; Beleboni RO; Hermes-Lima M
    Comp Biochem Physiol A Mol Integr Physiol; 2007 Apr; 146(4):463-9. PubMed ID: 16962348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.